Overview

NorthStar
Development

Our focus is on providing a spectrum of non-uranium based radioisotopes for use in diagnosing and treating serious diseases. State-of-the-art equipment and facilities and a robust pipeline are planned to help patients in the U.S. and around the world.

MEETING THE UNITED STATES’
DEMAND FOR Tc-99m
REQUIRES

ACCELERATOR
Mo-99

NorthStar’s industry-leading technology ensures timely and efficient production and delivery of Mo-99. Our most efficient production process will convert accelerator Mo-100 into medically useful aMo-99.
SUPPLYING THE GROWING DEMAND
FOR ESSENTIAL RADIOISOTOPES
REQUIRES

NORTHSTAR’s
MANUFACTURING

Two state-of-the-art U.S. operations will provide expanded production, increased capacity and unrivaled reliability.

CREATING SOLUTIONS FOR
RADIOPHARMACEUTICAL DEMAND REQUIRES A

ROBUST
PIPELINE

We are advancing a broad pipeline to ensure clinicians and patients have access to the next generation of diagnostic and therapeutic radioisotopes.

LEVERAGING ADVANCED PROCESSES THAT ARE
ECO FRIENDLY

The advanced technologies employed at NorthStar produce benign and recyclable waste streams that are free of the toxic and radioactive waste associated with uranium-based production. In this way, the Mo-99 produced at NorthStar is significantly more environmentally friendly than current standards.